Gene sequencing is the fastest growing sub-sector in the field of genetics. According to the BBC forecast, the compound growth rate in 2015-2022 is 25.4%, the output value in 2015 is about 2.7 billion US dollars, and the output value in 2021 will reach 10.5 billion US dollars. In the entire gene sequencing industry chain, upstream is the sequencing instrument and reagent supplier, the middle reaches is the genetic testing service provider, and the downstream targets are hospitals, pharmaceutical companies, scientific research institutions and patients themselves. Because the technology related to the sequencer and core reagents is highly monopolized by foreign companies because of the high technical barriers, domestic enterprises are mostly testing service providers, which are concentrated in the midstream market. A common problem with these testing service providers is the reliance on upstream instrument and reagent suppliers, with little bargaining power and the difficulty of reducing costs. Therefore, in order to further master the right to speak and the right to self-pricing, the development of domestic independent sequencers needs to set sail. Shenzhen Bohai Gene is a bio-tech company founded in 2012 by Stanford University and the University of Michigan PhD student team. The company currently has a team of world-class scientists in the field of gene sequencing technology, including mechanical, chemical, biological, optical, etc. A strong single-molecule sequencer R&D team composed of doctors from universities or research institutes at home and abroad. With the strong support of the government and private institutions, it has successfully developed the first single-molecule sequencer in Asia. Bohai Gene CEO He Jiankui and GenoCare Sequencer In August 2015, Bohai Gene carried out a project roadshow on the Demohealth platform and received the attention of many investors. The on-site discussion was extremely popular and showed strong interest in the three generations of single-molecule sequencers of Bohai Gene. In a few short years, Bohai Gene entered the rapid development track, and its leading third-generation sequencing technology attracted the attention and recognition of many top US investment banks, law firms and intellectual property institutions. Since its establishment, Bohai Gene has passed three rounds of financing, with a financing amount of over 100 million, and was selected into the Shenzhen Peacock Team this year. In addition, the company has already carried out early cooperation with three hospitals in Guangdong Province. The pilot project has non-invasive prenatal testing of Down's syndrome and other chromosome trisomy, as well as the detection of panel and 100 genetic diseases including 50 cancer genes. . In January of this year, Bohai Gene signed the first non-invasive prenatal testing client, Hong Kong Hemei Medical , a publicly traded company with 30 women and children hospitals. Faced with the competitive monopoly of the upstream market of gene sequencing, Bohai Gene has almost cut into a blue ocean market, just like a group of "dark horses", and has made a big break in the Chinese gene sequencing community. In order to gain a deeper understanding of how the Bohai Gene quickly mastered the third-generation gene side sequencer technology in the short term, Dr. Li Wei and Dr. Wu Zhisheng from the Demohealth team visited Shenzhen Bohai Gene Company on December 22, 2016. The company's Dr. Guo Youling warmly welcomed the team of Demohealth team and gave a detailed explanation of the technical research status and application potential of the three generations of single-molecule sequencers. Leading the sea to bring genetic sequencing to China's independent research and development era The second-generation sequencing technology has become the mainstream sequencing technology with its advantages of large throughput, high precision and relatively low price. Due to the strong patent protection and high technical threshold, the second-generation sequencing instrument manufacturing market has high barriers and has been monopolized by European and American companies. Major companies include Illumina, Life Tech (acquired by Thermo Scientific) and Roche. Among them, Illumina has a market share of over 70% due to its ultra-high throughput and relatively long read length. In order to change this situation, Bohai Gene has been focusing on the development of gene sequencers since its inception, and has created the first single-molecule gene sequencing platform for clinical medicine. On the basis of this platform, we will work together with clinicians and research scholars to promote the development of the genetic sequencing industry and the construction of precision medicine , so that genetic technology can serve human health and health. He Jiankui, CEO of Bohai Gene, once said: "The emergence of Bohai Gene, directly beyond the cumbersome, time-consuming and costly of second-generation sequencing, has entered the era of independent research and development in China." From the perspective of technology licensing and independent research and development, At present, there is no successful case in the development of the third-generation single-molecule sequencer at this stage in China. Throughout the entire international market, only the US Pacific Bio, the British Oxford Nanopod and the Shenzhen Bohai Gene are doing the third generation of genetic sequencers. It can be said that the emergence of the Bohai Gene allows China's gene sequencing technology to form a "three-legged" directly with Europe and the United States, bringing the genetic sequencer into the era of independent research and development in China, and changing the market structure of the genetic sequencer. Best Electric Face Brush,Best Facial Cleansing Brush,Electric Silicone Face Brush,Best Facial Cleansing Device Shenzhen Jie Zhong Lian Investment Co., Ltd. , https://www.szmeizon.com